COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01909453
Previous Study | Return to List | Next Study

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01909453
Recruitment Status : Active, not recruiting
First Posted : July 26, 2013
Last Update Posted : January 6, 2021
Sponsor:
Information provided by (Responsible Party):
Pfizer

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : November 9, 2016
Estimated Study Completion Date : August 31, 2022
Certification/Extension First Submitted : October 12, 2017
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):